公开(公告)号：KR1020150025697A

公开(公告)日：2015-03-11

申请号：KR1020130103648

申请日：2013-08-30

Applicant: 서울대학교산학협력단

Inventor： 조제열 ,  윤경애

IPC: C12Q1/68 ,  G01N33/68 ,  C12N15/11

CPC classification number: C12Q1/68 ,  C12Q2600/158 ,  G01N33/6857 ,  G01N33/6893

Abstract: The present invention relates to a method for screening formulations used for preventing or treating diseases related to FGF2, which comprises a step of measuring the level of CXCL5 in cells for making bones and vascular endothelial cells processed with FGF2 and candidate materials to prevent or treat diseases related to FGF2 including clone myeloblastic cellular diseases, a screening kit used in the screening method and a formulation obtained by the screening method for treating or preventing diseases related to FGF2. In the present invention, using the screening method is allowed to easily screen the formulation with a high reliability wherein the formulation is used for treating or preventing diseases related to bones caused by excesses FGF2 and other diseases related to hematopoietic stem cells like an effect on movement of hematopoietic stem cell series in bone marrow by the change of bone, thereby being used for manufacturing drugs to treat or prevent diseases related to FGF2 or to hematopoietic stem cell series.

Abstract translation: 本发明涉及筛选用于预防或治疗与FGF2有关的疾病的制剂的方法，该方法包括测量用于制备用FGF2加工的骨骼和血管内皮细胞的细胞中CXCL5的水平和预防或治疗疾病的候选物质的步骤 与FGF2相关，包括克隆成髓细胞疾病，用于筛选方法的筛选试剂盒和通过筛选方法获得的用于治疗或预防与FGF2有关的疾病的制剂。 在本发明中，允许使用筛选方法以高可靠性容易地筛选制剂，其中所述制剂用于治疗或预防与过量的FGF2引起的骨骼相关的疾病和与造血干细胞相关的其它疾病，如对运动的影响 的造血干细胞系列在骨髓中的变化，从而被用于制造药物以治疗或预防与FGF2相关的疾病或造血干细胞系列。